Analytical Data
-
Gene name
SF3B14
- Application
-
Alternative Names
SF3B6;SAP14;SF3B14;SF3B14A;Splicing factor 3B subunit 6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y3B4
-
Expression Region
1-125aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MAMQAAKRAN IRLPPEVNRI LYIRNLPYKI TAEEMYDIFG KYGPIRQIRV GNTPETRGTA YVVYEDIFDA KNACDHLSGF NVCNRYLVVL YYNANRAFQK MDTKKKEEQL KLLKEKYGIN TDPPK
-
Molecular Weight
17 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SF3B14 is a vital component of the spliceosome, a complex responsible for pre-mRNA splicing, which is a crucial process in gene expression regulation. Aberrations in splicing mechanisms are linked to various diseases, including cancer, neurodegenerative disorders, and genetic diseases, highlighting the importance of understanding the functional roles of spliceosomal components. Research on SF3B14 specifically focuses on its role in splice site recognition and the modulation of splicing efficiency, as well as its interactions with other splicing factors. Recent studies have indicated that SF3B14 may have implications in alternative splicing regulation, influencing the diversity of the transcriptome and, subsequently, protein diversity. Moreover, as SF3B14 is part of the larger SF3B complex, understanding its structure and function could pave the way for the development of targeted therapies that address splicing-related pathologies. By characterizing the SF3B14 recombinant protein, researchers aim to elucidate its molecular mechanisms and potential as a therapeutic target, fostering advancements in the treatment of splicing-related diseases.
